Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of short-term temporary discontinuation of serotonin reuptake inhibitors in patients planned for hip or knee arthroplasty
2023-509988-24-00Phase 4Withdrawn
- Sponsor
- Sygehus Lillebælt
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of duloxetine, sertraline, paroxetine, escitalopram and citalopram in major depressive disorder (MDD) and anxiety disorder, sponsored by Sygehus Lillebælt. Planned start Mar 2024; status: withdrawn.
02
Drugs
duloxetinesertralineparoxetineescitalopramcitalopram
03
Conditions
major depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on 2023-509988-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509988-24-00.